Review ArticleReview Article
Open Access

Current controversies in the management of patients with indeterminate thyroid nodules

Saad M. Alqahtani
Saudi Medical Journal July 2023, 44 (7) 633-639; DOI: https://doi.org/10.15537/smj.2023.44.7.2023-0049

References

  1. 1.↵
    2. McIver B.
    Evaluation of the thyroid nodule. Oral Oncol 2013; 49: 645–653.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Alqahtani SM ,
    3. Alanesi SF ,
    4. Mahmood WS ,
    5. Moustafa YM ,
    6. Moharram LM ,
    7. Alharthi NF , et al.
    Clinical and ultrasonographic features in cancer risk stratification of indeterminate thyroid nodules. Saudi Med J 2022; 43: 473–478.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    2. Barroeta JE ,
    3. Wang H ,
    4. Shiina N ,
    5. Gupta PK
    , LiVolsi VA, Baloch ZW. Is fine-needle aspiration (FNA) of multiple thyroid nodules justified? Endocr Pathol 2006; 17: 61–65.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Kotecka-Blicharz A ,
    3. Pfeifer A ,
    4. Czarniecka A ,
    5. Oczko-Wojciechowska M ,
    6. Nożyńska E ,
    7. Chmielik E , et al.
    Thyroid nodules with indeterminate cytopathology: a constant challenge in everyday practice. The effectiveness of clinical decisions using diagnostic tools available in Poland. Pol Arch Intern Med 2021; 131: 16117.
    OpenUrl
  5. 5.↵
    2. Trimboli P ,
    3. Treglia G ,
    4. Guidobaldi L ,
    5. Saggiorato E ,
    6. Nigri G ,
    7. Crescenzi A , et al.
    Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis. Endocrine 2014; 46: 52–59.
    OpenUrl
  6. 6.↵
    2. Cibas ES ,
    3. Ali SZ.
    The Bethesda system for reporting thyroid cytopathology. Thyroid 2009; 19: 1159–1165.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Cibas ES ,
    3. Ali SZ
    . The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 2017; 27: 1341–1346.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Haugen BR ,
    3. Alexander EK ,
    4. Bible KC ,
    5. Doherty GM ,
    6. Mandel SJ ,
    7. Nikiforov YE , et al.
    2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1–133.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. White MK ,
    3. Thedinger WB ,
    4. Dhingra JK.
    Long-term follow-up of cytologically indeterminate thyroid nodules found benign on molecular testing: A validation study. OTO Open 2022; 6: 2473974X221083542.
  10. 10.↵
    2. Kaliszewski K ,
    3. Diakowska D ,
    4. Rzeszutko M ,
    5. Nowak Ł ,
    6. Wojtczak B ,
    7. Sutkowski K , et al.
    Assessment of preoperative TSH serum level and thyroid cancer occurrence in patients with AUS/FLUS thyroid nodule diagnosis. Biomedicines 2022; 10: 1916.
    OpenUrl
  11. 11.↵
    2. Barbosa TLM ,
    3. Junior COM ,
    4. Graf H ,
    5. Cavalvanti T ,
    6. Trippia MA ,
    7. da Silveira Ugino RT , et al.
    ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology. BMC Endocr Disord 2019; 19: 112.
    OpenUrl
  12. 12.
    2. Batawil N ,
    3. Alkordy T.
    Ultrasonographic features associated with malignancy in cytologically indeterminate thyroid nodules. Eur J Surg Oncol 2014; 40: 182–186.
    OpenUrl
  13. 13.↵
    2. Alqahtani S ,
    3. Alsobhi S ,
    4. Alsalloum RI ,
    5. Najjar SN ,
    6. Al-Hindi HN.
    Surgical outcome of thyroid nodules with atypia of undetermined significance and follicular lesion of undetermined significance in fine needle aspiration biopsy. World J Endocr Surg 2017; 9: 100–103.
    OpenUrl
  14. 14.
    2. Al-Hakami HA ,
    3. Al-Mohammadi R ,
    4. Al-Mutairi R ,
    5. Al-Subaie H ,
    6. Al Garni MA.
    McGill thyroid nodule score in differentiating thyroid nodules in total thyroidectomy cases of indeterminate nodules. Indian J Surg Oncol 2020; 11: 268–273.
    OpenUrl
  15. 15.
    2. Alshahrani AS ,
    3. Alamri AS ,
    4. Balkhoyor AH ,
    5. Mahzari MM ,
    6. Alshieban SS ,
    7. Majed PM.
    The prediction of malignancy risk in thyroid nodules classified as Bethesda system Category III (AUS/FLUS) and the role of ultrasound finding for prediction of malignancy risk. Cureus 2021; 13: e17924.
    OpenUrl
  16. 16.
    2. Alyousif H ,
    3. Adam I ,
    4. Alamin NA ,
    5. Sid Ahmed MA ,
    6. Al Saeed A ,
    7. Hassoni AH , et al.
    The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia. Ther Adv Endocrinol Metab 2022; 13: 20420188221122486.
    OpenUrl
  17. 17.↵
    2. Alqahtani SM ,
    3. Al-Sobhi SS ,
    4. Alturiqy MA ,
    5. Alsalloum RI ,
    6. Al-Hindi HN.
    The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules. J Taibah Univ Med Sci 2022; 18: 506–511.
    OpenUrl
  18. 18.↵
    2. Agrawal NK
    2. Mittal M ,
    3. Ganakumar V ,
    4. Shukla R ,
    5. Kumar G.
    Thyroid nodule: approach and management. In: Agrawal NK (ed.) Goiter - causes and treatment. IntechOpen: London; 2020.
  19. 19.↵
    2. Teixeira GV ,
    3. Chikota H ,
    4. Teixeira T ,
    5. Manfro G ,
    6. Pai SI ,
    7. Tufano RP.
    Incidence of malignancy in thyroid nodules determined to be follicular lesions of undetermined significance on fine-needle aspiration. World J Surg 2012; 36: 69–74.
    OpenUrlPubMedWeb of Science
  20. 20.
    2. Nagarkatti SS ,
    3. Faquin WC ,
    4. Lubitz CC ,
    5. Garcia DM ,
    6. Barbesino G ,
    7. Ross DS , et al.
    Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy. Ann Surg Oncol 2013; 20: 60–65.
    OpenUrl
  21. 21.↵
    2. Park VY ,
    3. Kim EK ,
    4. Kwak JY ,
    5. Yoon JH ,
    6. Moon HJ.
    Malignancy risk and characteristics of thyroid nodules with two consecutive results of atypia of undetermined significance or follicular lesion of undetermined significance on cytology. Eur Radiol 2015; 25: 2601–2607.
    OpenUrl
  22. 22.↵
    2. Sorrenti S ,
    3. Trimboli P ,
    4. Catania A ,
    5. Ulisse S ,
    6. De Antoni E ,
    7. D’Armiento M.
    Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm. Thyroid 2009; 19: 355–360.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Ho AS ,
    3. Sarti EE ,
    4. Jain KS ,
    5. Wang H ,
    6. Nixon IJ ,
    7. Shaha AR , et al.
    Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid 2014; 24: 832–839.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Al Dawish M ,
    3. Alwin Robert A ,
    4. Al Shehri K ,
    5. Hawsawi S ,
    6. Mujammami M ,
    7. Al Basha IA , et al.
    Risk stratification of thyroid nodules with Bethesda III category: the experience of a territorial healthcare hospital. Cureus 2020; 12: e8202.
    OpenUrl
  25. 25.↵
    2. Durante C ,
    3. Pecce V ,
    4. Grani G.
    Management of cytologically indeterminate thyroid nodules: primum non nocere. Pol Arch Intern Med 2021; 131: 16166.
    OpenUrl
  26. 26.↵
    2. Jooya A ,
    3. Saliba J ,
    4. Blackburn A ,
    5. Tamilia M ,
    6. Hier MP ,
    7. Mlynarek A , et al.
    The role of repeat fine needle aspiration in the management of indeterminate thyroid nodules. J Otolaryngol Head Neck Surg 2016; 45: 51.
    OpenUrl
  27. 27.↵
    2. Chen JC ,
    3. Pace SC ,
    4. Khiyami A ,
    5. McHenry CR.
    Should atypia of undetermined significance be subclassified to better estimate risk of thyroid cancer? Am J Surg 2014; 207: 331–336.
    OpenUrl
  28. 28.↵
    2. Broome JT ,
    3. Cate F ,
    4. Solorzano CC.
    Utilization and impact of repeat biopsy for follicular lesion/atypia of undetermined significance. World J Surg 2014; 38: 628–633.
    OpenUrl
  29. 29.↵
    2. Valerio E ,
    3. Pastorello RG ,
    4. Calsavara V ,
    5. Porfírio MM ,
    6. Engelman GG ,
    7. Francisco Dalcin J , et al.
    Should we wait 3 months for a repeat aspiration in non‐diagnostic/indeterminate thyroid nodules? A cancer centre experience. Cytopathology 2020; 31: 525–532.
    OpenUrl
  30. 30.↵
    2. Bayona A ,
    3. Benavent P ,
    4. Muriel A ,
    5. Abuchaibe C ,
    6. Sharpe SC ,
    7. Tarasova V , et al.
    Outcomes of repeat fine needle aspiration biopsy for AUS/FLUS thyroid nodules. Eur J Endocrinol 2021; 185: 497–506.
    OpenUrl
  31. 31.↵
    2. Horvath E ,
    3. Majlis S ,
    4. Rossi R ,
    5. Franco C ,
    6. Niedmann JP ,
    7. Castro A , et al.
    An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009; 94: 1748–1751.
    OpenUrlCrossRefPubMed
  32. 32.
    2. Park JY ,
    3. Lee HJ ,
    4. Jang HW ,
    5. Kim HK ,
    6. Yi JH ,
    7. Lee W , et al.
    A proposal for a thyroid imaging reporting and data system for ultrasound features of thyroid carcinoma. Thyroid 2009; 19: 1257–1264.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.
    2. Kwak JY ,
    3. Han KH ,
    4. Yoon JH ,
    5. Moon HJ ,
    6. Son EJ ,
    7. Park SH , et al.
    Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 2011; 260: 892–899.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.
    2. Russ G ,
    3. Bigorgne C ,
    4. Royer B ,
    5. Rouxel A ,
    6. Bienvenu-Perrard M.
    [The Thyroid Imaging Reporting and Data System (TIRADS) for ultrasound of the thyroid.] (in French) J Radiol 2011; 92: 701–713.
    OpenUrlPubMedWeb of Science
  35. 35.
    2. Russ G ,
    3. Royer B ,
    4. Bigorgne C ,
    5. Rouxel A ,
    6. Bienvenu-Perrard M ,
    7. Leenhardt L.
    Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. Eur J Endocrinol 2013; 168: 649–655.
    OpenUrlAbstract/FREE Full Text
  36. 36.
    2. Tessler FN ,
    3. Middleton WD ,
    4. Grant EG ,
    5. Hoang JK ,
    6. Berland LL ,
    7. Teefey SA , et al.
    ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee. J Am Coll Radiol 2017; 14: 587–595.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Modi L ,
    3. Sun W ,
    4. Shafizadeh N ,
    5. Negron R ,
    6. Yee‐Chang M ,
    7. Zhou F , et al.
    Does a higher American College of Radiology thyroid Imaging Reporting and Data System (ACR TI‐RADS) score forecast an increased risk of malignancy? A correlation study of ACR TI‐RADS with FNA cytology in the evaluation of thyroid nodules. Cancer Cytopathol 2020; 128: 470–481.
    OpenUrl
  38. 38.↵
    2. Eisa N ,
    3. Khan A ,
    4. Akhter M ,
    5. Fensterwald M ,
    6. Saleem S ,
    7. Fananapazir G , et al.
    Both ultrasound features and nuclear atypia are associated with malignancy in thyroid nodules with atypia of undetermined significance. Ann Surg Oncol 2018; 25: 3913–3918.
    OpenUrl
  39. 39.↵
    2. Kang S ,
    3. Kwon SK ,
    4. Choi HS ,
    5. Kim MJ ,
    6. Park YJ ,
    7. Park DJ , et al.
    Comparison of Korean vs. American thyroid Imaging Reporting and Data System in malignancy risk assessment of indeterminate thyroid nodules. Endocrinol Metab (Seoul) 2021; 36: 1111–1120.
    OpenUrl
  40. 40.↵
    2. De D ,
    3. Dutta S ,
    4. Tarafdar S ,
    5. Kar SS ,
    6. Das U ,
    7. Basu K , et al.
    Comparison between sonographic features and fine needle aspiration cytology with histopathology in the diagnosis of solitary thyroid nodule. Indian J Endocrinol Metab 2020; 24: 349–354.
    OpenUrl
  41. 41.↵
    2. Cozzani F ,
    3. Bettini D ,
    4. Rossini M ,
    5. Bonati E ,
    6. Nuzzo S ,
    7. Loderer T , et al.
    Thyroid nodules with indeterminate cytology: association between nodule size, histopathological characteristics and clinical outcome in differentiated thyroid carcinomas—A multicenter retrospective cohort study on 761 patients. Updates Surg 2021; 73: 1923–1930.
    OpenUrl
  42. 42.↵
    2. Valderrabano P ,
    3. Khazai L ,
    4. Thompson ZJ ,
    5. Otto KJ ,
    6. Hallanger-Johnson JE ,
    7. Chung CH , et al.
    Association of tumor size with histologic and clinical outcomes among patients with cytologically indeterminate thyroid nodules. JAMA Otolaryngol Head Neck Surg 2018; 144: 788–795.
    OpenUrl
  43. 43.↵
    2. Piccardo A ,
    3. Puntoni M ,
    4. Treglia G ,
    5. Foppiani L ,
    6. Bertagna F ,
    7. Paparo F , et al.
    Thyroid nodules with indeterminate cytology: prospective comparison between 18F-FDG-PET/CT, multiparametric neck ultrasonography, 99mTc-MIBI scintigraphy and histology. Eur J Endocrinol 2016; 174: 693–703.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    2. Karatzas T ,
    3. Vasileiadis I ,
    4. Zapanti E ,
    5. Charitoudis G ,
    6. Karakostas E ,
    7. Boutzios G.
    Thyroglobulin antibodies as a potential predictive marker of papillary thyroid carcinoma in patients with indeterminate cytology. Am J Surg 2016; 212: 946–952.
    OpenUrl
  45. 45.
    2. Calò PG ,
    3. Medas F ,
    4. Santa Cruz R ,
    5. Podda F ,
    6. Erdas E ,
    7. Pisano G , et al.
    Follicular nodules (Thy3) of the thyroid: is total thyroidectomy the best option? BMC Surg 2014; 14: 12.
    OpenUrlCrossRefPubMed
  46. 46.
    2. Kato MA ,
    3. Buitrago D ,
    4. Moo TA ,
    5. Keutgen XM ,
    6. Hoda RS ,
    7. Ricci JA , et al.
    Predictive value of cytologic atypia in indeterminate thyroid fine-needle aspirate biopsies. Ann Surg Oncol 2011; 18: 2893–2898.
    OpenUrlPubMedWeb of Science
  47. 47.↵
    2. Almquist M ,
    3. Muth A.
    Surgical management of cytologically indeterminate thyroid nodules. Gland Surg 2019; 8(Suppl 2): S105–S111.
    OpenUrl
  48. 48.↵
    2. Schneider DF ,
    3. Cherney Stafford LMC ,
    4. Brys N ,
    5. Greenberg CC ,
    6. Balentine CJ ,
    7. Elfenbein DM , et al.
    Gauging the extent of thyroidectomy for indeterminate thyroid nodules: an oncologic perspective. Endocr Pract 2017; 23: 442–450.
    OpenUrl
  49. 49.↵
    2. Duick DS ,
    3. Klopper JP ,
    4. Diggans JC ,
    5. Friedman L ,
    6. Kennedy GC ,
    7. Lanman RB , et al.
    The impact of benign gene expression classifier test results on the endocrinologist–patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid 2012; 22: 996–1001.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    2. Lim JXY ,
    3. Nga ME ,
    4. Chan DKH ,
    5. Tan WB ,
    6. Parameswaran R ,
    7. Ngiam KY.
    Subclassification of Bethesda atypical and follicular neoplasm categories according to nuclear and architectural atypia improves discrimination of thyroid malignancy risk. Thyroid 2018; 28: 511–521.
    OpenUrl
  51. 51.↵
    2. Yoo WS ,
    3. Ahn HY ,
    4. Ahn HS ,
    5. Chung YJ ,
    6. Kim HS ,
    7. Cho BY , et al.
    Malignancy rate of Bethesda category III thyroid nodules according to ultrasound risk stratification system and cytological subtype. Medicine (Baltimore) 2020; 99: e18780.
  52. 52.↵
    2. Haymart MR ,
    3. Repplinger DJ ,
    4. Leverson GE ,
    5. Elson DF ,
    6. Sippel RS ,
    7. Jaume JC , et al.
    Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008; 93: 809–814.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.
    2. Muzza M ,
    3. Degl’Innocenti D ,
    4. Colombo C ,
    5. Perrino M ,
    6. Ravasi E ,
    7. Rossi S , et al.
    The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) 2010; 72: 702–708.
    OpenUrlCrossRefPubMed
  54. 54.
    2. Hosseini S ,
    3. Payne RJ ,
    4. Zawawi F ,
    5. Mlynarek A ,
    6. Hier MP ,
    7. Tamilia M , et al.
    Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer? J Otolaryngol Head Neck Surg 2016; 45: 31.
    OpenUrl
  55. 55.↵
    2. Vasileiadis I ,
    3. Boutzios G ,
    4. Charitoudis G ,
    5. Koukoulioti E ,
    6. Karatzas T.
    Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol 2014; 21: 2725–2732.
    OpenUrlCrossRefPubMed
  56. 56.
    2. Golbert L ,
    3. de Cristo AP ,
    4. Faccin CS ,
    5. Farenzena M ,
    6. Folgierini H ,
    7. Graudenz MS , et al.
    Serum TSH levels as a predictor of malignancy in thyroid nodules: A prospective study. PLoS One 2017; 12: e0188123.
    OpenUrl
  57. 57.↵
    2. Boi F ,
    3. Minerba L ,
    4. Lai ML ,
    5. Marziani B ,
    6. Figus B ,
    7. Spanu F , et al.
    Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest 2013; 36: 313–320.
    OpenUrl
  58. 58.↵
    2. Adhami M ,
    3. Michail P ,
    4. Rao A ,
    5. Bhatt CR ,
    6. Grodski S ,
    7. Serpell JW , et al.
    Anti-thyroid antibodies and TSH as potential markers of thyroid carcinoma and aggressive behavior in patients with indeterminate fine-needle aspiration cytology. World J Surg 2020; 44: 363–370.
    OpenUrl
  59. 59.↵
    2. Al Dawish MA ,
    3. Alwin Robert A ,
    4. Thabet MA ,
    5. Braham R.
    Thyroid nodule management: thyroid-stimulating hormone, ultrasound, and cytological classification system for predicting malignancy. Cancer Inform 2018; 17: 1176935118765132.
    OpenUrl
  60. 60.↵
    2. Zafon C ,
    3. Obiols G ,
    4. Baena JA ,
    5. Castellví J ,
    6. Dalama B ,
    7. Mesa J.
    Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size. J Thyroid Res 2012; 2012: 530721.
    OpenUrlPubMed
  61. 61.↵
    2. Gudmundsson J ,
    3. Sulem P ,
    4. Gudbjartsson DF ,
    5. Jonasson JG ,
    6. Masson G ,
    7. He H , et al.
    Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet 2012; 44: 319–322.
    OpenUrlCrossRefPubMed
  62. 62.↵
    2. Fiore E ,
    3. Rago T ,
    4. Provenzale MA ,
    5. Scutari M ,
    6. Ugolini C ,
    7. Basolo F , et al.
    L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. Endocr Relat Cancer 2010; 17: 231–239.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords